MedTrace Logo

Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy

NCT03433326 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2018-02-14

No results posted yet for this study

Summary

CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12 weeks without Ribavirin in patients with HCV chronic hepatitis (G1b and G4) and cryoglobulinemic nephropathy.

Conditions

  • Hepatitis C
  • Cryoglobulinaemic Glomerulonephritis

Interventions

DRUG

Elbasvir/Grazoprevir

Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks

Sponsors & Collaborators

  • University of Florence

    lead OTHER

Principal Investigators

  • ANNA LINDA ZIGNEGO, MD, PhD · University of Florence

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2018-12-31
Completion
2018-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03433326 on ClinicalTrials.gov